Aktuelle Forschungsansätze bei ADHS

Kerstin Konrad; Johannes Hebebrand; Beate Herpertz-Dahlmann

doi:10.1055/s-0037-1617787

Kinder- und Jugendmedizin, Table of Contents

Kinder- und Jugendmedizin 2003; 3(04): 161-166
DOI: 10.1055/s-0037-1617787

Hyperkinetische Störungen

Schattauer GmbH

Aktuelle Forschungsansätze bei ADHS

Research perspectives in ADHD

Kerstin Konrad

¹Klinik für Kinder- und Jugendpsychiatrie und -psychotherapie der Universität Aachen (Direktor: Prof. Dr. med. Beate Herpertz-Dahlmann)

,

Johannes Hebebrand

²Klinik für Psychiatrie und Psychotherapie des Kindes- und Jugendalters Marburg (Direktor: Prof. Dr. Dr. H. Remschmidt)

,

Beate Herpertz-Dahlmann

¹Klinik für Kinder- und Jugendpsychiatrie und -psychotherapie der Universität Aachen (Direktor: Prof. Dr. med. Beate Herpertz-Dahlmann)

› Author Affiliations

Abstract

Zusammenfassung

Im folgenden Kapitel werden der derzeitige Forschungsstand zu Epidemiologie, Ätiologie, Diagnostik und Behandlung der Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) zusammengefasst und weitergehende Perspektiven diskutiert.

Summary

The current article reviews the state of the art of epidemiology, etiology, diagnostic assessment and treatment of attention deficit/hyperactivity disorder (ADHD). Future research perspectives will be discussed.

Schlüsselwörter

Forschung - ADHS

Keywords

Research perspectives - ADHD

Full Text

References

Literatur
1 Ahmann PA, Theye FW, Berg R, Linquist AJ, Van Erem AJ, Campbell LR. Placebo-controlled evaluation of amphetamine mixturedextroamphetamine salts and amphetamine salts (Adderall): efficacy rate and side effects. Petriatrics 2001; 107: E10.
2 Arnsten AF, Steere JC, Hunt RD. The contribution of alpha 2-noradrenergic mechanisms of prefrontal cortical cognitive function. Potential significance for attention-deficit hyperactivity disorder. Arch Gen Psychiatry 1996; 53: 448-55.
3 Barbaresi WJ, Katusic SK, Colligan RC, Pankratz VS, Weaver AL, Weber KJ, Mrazek DA, Jacobsen SJ. How common is attention-deficit/hyperactivity disorder? Incidence in a population-based birth cohort in Rochester, Minn. Arch Pediatr Adolesc Med 2002; 156: 217-24.
4 Baumgaertel A, Wolraich ML, Dietrich M. Comparison of diagnostic criteria for attention deficit disorders in a German elementary school sample. J Am Acad Child Adolesc Psychiatry 1995; 34: 629-38.
5 Berquin PC, Giedd JN, Jacobsen LK, Hamburger SD, Krain AL, Rapoport JL, Castellanos FX. Cerebellum in attention-deficit hyperactivity disorder: a morphometric MRI study. Neurology 1998; 50 (04) 1087-93.
6 Conners CK, Sitarenios G, Parker JD, Epstein JN. The revised Conners’ Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol 1998; 26 (04) 257-68.
7 Döpfner M, Lehmkuhl G. Diagnose- und Symptomchecklisten zur Erfassung psychischer Störungen im Kindes- und Jugendalter nach ICD-10 und DSM IV. Göttingen: Hogrefe; 1996
8 Faraone SV, Biederman J, Roe C. Comparative efficacy of Adderall and methylphenidate in attention-deficit/hyperactivity disorder: a meta-analysis. J Clin Psychopharmacol 2002; 22: 468-73.
9 Gainetdinov RR, Wetsel WC, Jones SR, Levin ED, Jaber M, Caron MG. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science 1999; 283 (5400) 397-401.
10 Goldman LS, Genel M, Bezman RJ, Slanetz PJ. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. JAMA 1998; 279: 1100-7.
11 Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J, Benson RS, Bukstein O, Kinlan J, McClellan J, Rue D, Shaw JA, Stock S. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002; 41: 26S-49S.
12 Kratochvil CJ, Heiligenstein JH, Dittmann R, Spencer TJ, Biederman J, Wernicke J, Newcorn JH, Casat C, Milton D, Michelson D. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, openlabel trial. J Am Acad Child Adolesc Psychiatry 2002; 41: 776-84.
13 Lauth GW, Lamberti J. Prävalenz von Aufmerksamkeits-/Hyperaktivitätsstörungen in der Grundschule – eine epidemiologische Pilotuntersuchung. Kindheit und Entwicklung 1997; 6: 197-205.
14 LeFever GB, Dawson KV, Morrow AL. The extent of drug therapy for attention deficit-hyperactivity disorder among children in public schools. Am J Public Health 1999; 89: 1359-64.
15 Lehmkuhl G, Döpfner M. Behandlung des hyperkinetischen Syndroms. In: Bundesärztekammer (Hrsg).. Fortschritt und Fortbildung in der Medizin. Köln: Deutscher Ärzteverlag; 2002: 20-8.
16 Mefford IN, Potter WZ. A neuroanatomical and biochemical basis for attention deficit disorder with hyperactivity in children: a defect in tonic adrenaline mediated inhibition of locus coeruleus stimulation. Med Hypotheses 1989; 29 (01) 33-42.
17 Pliszka SR, McCracken JT, Maas JW. Catecholamines in Attention-Deficit Hyperactivity Disorder: Current perspectives. J Am Acad Child Adolesc Psychiatry 1996; 35: 264-71.
18 Posner MI, Raichle ME. Networks of attention. In: Posner MI, Raichle ME. (ed). Images of mind. New York: Scientific American Library; 1994: 153-79.
19 Quist JF, Kennedy JL. Genetics of childhood disorders. ADHD, Part 7, The Serotonin System. J Am Acad Child Adoles Psychiatry 2001; 40 (02) 253-6.
20 Resch F, Rothenberger A. Aufmerksamkeitsdefizit-Hyperaktivitätsstörung (ADHS) und Stimulantien. Editorial. Kinder-Jugendpsychiatr 2002; 30: 159-61.
21 Shenker A. The mechanism of action of drugs used to treat attention-deficit hyperactivity disorder: focus on catecholamine receptor pharmacology. Adv Pediatr 1992; 39: 337-82.
22 Swanson J, Gupta S, Lam A, Shoulson I, Lerner M, Modi N, Lindenmulder E, Wigal S. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-ofconcept and proof-of-product studies. Arch Gen Psychiatry 2003; 60: 204-11.
23 Swanson J, Gupta S, Williams L, Agler D, Lerner M, Wigal S. Efficacy of a new pattern of delivery of methylphenidate for the treatment of ADHD: effects on activity level in the classroom and on the playground. J Am Child Adolesc Psychiatry 2002; 41: 1306-14.
24 Swanson JM, Flodman P, Kennedy J, Spence MA, Moyzis R, Schuck S, Murias M, Moriarity J, Barr C, Smith M, Posner M. Dopamine genes and ADHD. Neurosci Biobehav Rev 2000; 24: 21-5.
25 Tulloch SJ, Zhang Y, McLean A, Wolf KN. SLI381 (Adderall XR), a two-component, extended-release formulation of mixed amphetamine salts: bioavailability of three test formulations and comparison of fasted, fed, and sprinkled administration. Pharmacotherapy 2002; 22: 1405-15.
26 Vaidya CJ, Austin G, Kirkorian G. Selective effects of methylphenidate in attention deficit hyperactivity disorder: A functional magnetic resonance study. Proc Natl Acad Sci USA 1998; 95: 14494-9.
27 Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Logan J, Ding YS, Dewey SL, Hitzemann R, Gifford AN, Pappas NR. Blockade of striatal dopamine transporters by intravenous methylphenidate is not sufficient to induce self-reports of »high«. J Pharmacol Experimental Therapy 1999; 288 (01) 14-20.
28 Wernicke JF, Kratochvil CJ. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J Clin Psychiatry 2002; 63: 50-5.
29 Wolraich ML, Hannah JN, Pinnock TY, Baumgaertel A, Brown J. Comparison of diagnostic criteria for attention-deficit hyperactivity disorder in a county-wide sample. J Am Acad Child Adolesc Psychiatry 1996; 35: 319-24.
30 Zito JM, Safer DJ, dosReis S, Gardner JF, Boles M, Lynch F. Trends in the prescribing of psychotropic medications to preschoolers. JAMA 2000; 283: 1025-30.